Novo and Viatris Settle Ozempic Patent Dispute Amid Generic Launch Plans

Novo Nordisk and Viatris subsidiary Mylan have reached a settlement over a patent dispute concerning the diabetes medication Ozempic, which is based on the molecule semaglutide. The details of the settlement are confidential, and it remains uncertain when generic versions will enter the U.S. market[1]. As part of the resolution, both companies requested the U.S. Patent and Trademark Office to halt its review of semaglutide's patent validity. This agreement paves the way for a potential generic launch by Mylan, in collaboration with Natco Pharma, especially since they have first-to-file rights for certain doses[2].